Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft

@inproceedings{Zhang2010AugmentedIO,
  title={Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft},
  author={Anli Zhang and Guodong Shen and Ting Zhao and Gui Zhang and Jing Liu and Lihua Song and Wei Wei and Ling Bing and Zheng-Sheng Wu and Qiang Wu},
  booktitle={Journal of ovarian research},
  year={2010}
}
BACKGROUND chA21 is a novel tumor-inhibitory antibody which recognized subdomain I of HER2 extracellular domain with an epitope distinct from other HER2 antibodies. Previously, we demonstrated that chA21 inhibits human ovarian carcinoma cell line SKOV-3 growth in vitro and in vivo study. In this study, we further investigated the anti-angiogenic efficacy combination of chA21 with trastuzumab in SKOV-3 xenograft model. METHODS Nude mice were s.c. challenged with SKOV-3 cells and received… CONTINUE READING